medigraphic.com
ISSN 1684-1824 (Electronic)

2021, Number 1

<< Back Next >>

Rev Méd Electrón 2021; 43 (1)

Survival of patients with non-small cells lung cancer in advanced stages. Matanzas

Camacho SK, Alonso LL, Ramírez RD, Carreño RIE, Mendoza JE, García SJ

Language: Spanish
References: 20
Page:
PDF size: 293.94 Kb.


ABSTRACT

Introduction: non-small cell lung cancer in advanced stages shows a high incidence and mortality. The treatments used against it are chemotherapy, radiotherapy, directed therapies and immunotherapy. It is better to perform the treatments in the context of clinical trials. It has a precarious survival at the fifth year after diagnosis.
Objective: to determine the global survival of patients with non-small cell lung cancer in advanced stages.
Materials and methods: descriptive, retrospective study in patients with cyto-histological diagnosis of non-small lung cancer in advanced stages. A sample of 348 patients was formed from the universe of 463 patients who attended the Provincial Service of Oncology in the period from January 2013 to December 2016. The studied variables were taken from the clinical records and the national database of deceased due to lung cancer.
Results: most of patients were diagnosed at the stage IV (71.69 %); the most used treatment modality was chemotherapy (61.2). The most used drugs were platinum salts in 78.73 %. The global survival at the IV stage was 1.23 at five years. The treatment modality of greater survival was immunotherapy, with 3.33 % and the global survival was 2 %.
Conclusions: the disease’s stage IV predominated. The platinum salts-based chemotherapy as the first line treatment scheme and immunotherapy as treatment modality provided higher global survival, although it was precarious.


REFERENCES

  1. Oncology.Pro. Thoracic Tumours: Essentials for Clinicians[Internet] EE UU: European Society for Medical Oncology; 2019[citado 26/12/2018] . Disponible en: Disponible en: https://oncologypro.esmo.org/education-library/essentials-for-clinicians/thoracic-tumours

  2. Ministerio de Salud Pública de Cuba. Anuario Estadístico 2018[Internet]. La Habana: MINSAP; 2019[citado26/12/2018].Disponible en: Disponible en: http://www.sld.cu/anuncio/2019/04/26/publicado-el-anuario-estadistico-de-salud-2018

  3. Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol[Internet]. 2016[citado26/12/2018]; 11:39-51.Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/26762738/

  4. American Cancer Society. Cáncer de pulmón no microcítico [Internet]. EE UU: American Cancer Society[citado 26/12/2018];2018.Disponible en: Disponible en: https://www.cancer.org/es/cancer/cancer-de-pulmon.html

  5. Planchard D, Popat S, Kerr K, et al. Metastatic non-small Cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. [Internet]. Ann Oncol[Internet]. 2018[citado 26/12/2018]; 29(suppl 4):iv192-iv237.Disponible en: Disponible en: https://www.annalsofoncology.org/article/S0923-7534(19)31710-7/pdf

  6. Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med[Internet]. 2017[citado 26/12/2018]; 376:629-40. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/27959700/

  7. Haanen JBAG, Lugowska I, Garassino MC, et al. ESMO Handbook of Immuno-Oncology. Lugano: ESMO Press; 2018.

  8. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med[Internet]. 2016[citado26/12/2018]; 375:1823-33. Disponible en: Disponible en: https://www.nejm.org/doi/full/10.1056/nejmoa1606774

  9. Cobián Caballero CO, Acosta Brooks SC, Martínez FeriaII F, Ibrahim Romero García L. Supervivencia en pacientes con cáncer pulmonar de células no pequeñas vacunados con CIMAvax-EGF. MEDISAN[Internet]. 2016[citado 26/12/2018]; 20(3):320. Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1029-30192016000300007

  10. Rodriguez P, Popa X, Martínez O, et al. A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients. Clin Cancer Res. 2016 ;22(15):3782-90. Citado en PubMed; PMID: 26927662.

  11. Pérez L, Estévez D, Gastón Y, et al. Seguridad del Racotumomab en el tratamiento de pacientes con cáncer de pulmón de células no pequeñas. VacciMonitor[Internet]. 2015[citado26/12/2018]; 22(1):10-14. Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2013000100003

  12. Hernandez M, Neninger E, Santiesteban E, et al. Efficacy of racotumomab or nimotuzumab vs docetaxel as secondline therapy for advanced non-small cell lung cancer patients. [Internet] Oncology Pro. 2018 [citado26/12/2018]; 29 ( Sup 8) :viii415. Disponible en: Disponible en: https://oncologypro.esmo.org/meeting-resources/esmo-2018-congress/Efficacy-of-racotumomab-or-nimotuzumab-vs-docetaxel-as-second-line-therapy-for-advanced-non-small-cell-lung-cancer-patients

  13. González Barcala FJ, Falagan JA, García-Prim JM, et al. Cáncer de pulmón en el área sanitaria de Pontevedra: incidencia, presentación clínica y supervivencia. [Internet]. An Sist Sanit Navar[Internet].2013[citado26/12/2018 ]; 36 (2): 217-27.Disponible en: Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1137-66272013000200005

  14. Díaz Toledo M, Cayón Escobar I, Crespo Díaz T, et al. Quimioterapia en cáncer de pulmón avanzado en pacientes mayores de 60 años de edad del Hospital Benéfico-Jurídico (2008-2011). [Internet]. Rev Habanera de Ciencias Médicas[Internet]. 2014[citado26/12/2018];13(2):227-37. Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1729-519X2014000200008

  15. De Vita VT J, Lawrence TS, Rosenberg SA: Cancer: Principles and Practice of Oncology [Internet].11th ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 2019[citado26/12/2018]. Disponible en: Disponible en: https://books.google.com.cu/books?hl=es&lr=&id=4IeKRZkWtHQC&oi=fnd&pg=PR5&dq=Principles+and+Practice+of+Oncology&ots=P33wJgGY70&sig=6snDRM1X7yEy48aVd_CUtwoBupo&redir_esc=y#v=onepage&q=Principles%20and%20Practice%20of%20Oncology&f=false

  16. NCCN. Clinical Practice Guidelines in Oncology. Lung Cancer [Internet]. EE UU: NCCN; 2019[citado 26/12/2018].Disponible en: Disponible en: https://www.nccn.org/professionals/

  17. Rafiemanesh H, Mehtarpour M, Khani F, et al. Epidemiología, incidencia y mortalidad del cáncer de pulmón y su relación con el índice de desarrollo en el mundo. J Thorac Dis [Internet]. 2016 [citado 26/12/2018 ];8(6):[aprox. 9 p. Disponible en: Disponible en: http://jtd.amegroups.com/article/view/7522/html

  18. Comisión clínica de cáncer de pulmón. Protocolo cáncer de pulmón. Diagnóstico, tratamiento y seguimiento [Internet]. Córdoba: Servicio Andaluz de Salud; 2015 [citado 22/10/2019]. Disponible en:Disponible en:https://www.sspa.juntadeandalucia.es/servicioandaluzdesalud/hrs3/fileadmin/user_upload/ area_medica/comite_tumores/cancer_pulmon.pdf

  19. Barbosa R, Bernal Perez MM, Costa IC, et al. Supervivencia del cáncer de pulmón pacientes tratados en un hospital de referencia en Zaragoza, España. Science direct[Internet]. 2016; 42 (6):380-87. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S113835931500266X

  20. Díaz A, Lage A. Terapias con inhibidores del receptor del factor de crecimiento epidérmico: acercando el futuro. Biotecnología Aplicada [Internet]. 2007; 24(1). Disponible en: https://elfosscientiae.cigb.edu.cu/PDFs/Biotecnol%20Apl/2007/24/1/BA002401RV001-009.pdf




2020     |     www.medigraphic.com